Advate Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (ADVATE rAHF-PFM): A Phase 4 Study Comparing Two Prophylactic Regimens in Subjects With Severe or Moderately Severe Hemophilia A
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Octocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Baxter BioScience; Baxter Healthcare Corporation
- 09 Dec 2013 New trial record